7Nakayama M,Amano M.Rho-kinase and myosin Ⅱ activities are required for cell type and environment specific migration[J].Genes to Cells,2005,10(2):107～117
8Waugh J,Keating G.Losartan:in the reduction of stroke risk in patients with hypertension and left ventricular hypertrophy[J].American Journal of Cardiovascular Drugs,2003,3(5):371～377
9Tadashi Yamakawa,Shun-ichi Tanaka,Kotaro Numaguchi,et al.Involvement of Rho-kinase in angiotensin Ⅱ-induced hypertrophy of rat vascular smooth muscle cells[J].Hypertension,2000,35;313～318
10Shimokawa,Takeshita A.Rho-Kinase is an important therapeutic target in cardiovascular medicine[J].Arterioscler Thromb Vasc Biol,2005,25(9):1757～1775
二级参考文献37
1[1]Aspenstrom P et al. Curr Opin Cell Biol,1999,11:95-102
2[2]Kjoller L et al. Experimental Cell Reasearch,1999,253:166-179
3[3]Takai Y et al. Physiol Rev,2001,81(1):153-208
4[4]Mackay DJ et al. J Biol Chem,1998,273(33):20685-20688
5[5]Hall A. Science,1998,279(5350):509-514
6[6]Erickson JW et al.Curr Opin Cell Biol,2001,13(2):153-157
7[7]Ridley AJ et al.Cell,1992,70(3):401-410
8[8]Marc S et al.Trends Cell Biol,2000,10(10):415-419
7Nakayama M, Amano M. Rho-kinase and myosin Ⅱ activities are required for cell type and environment specific migration[ J]. Genes to Cells,2005,10 (2) : 107 - 117.
8Eaton R, Su C, Valencia T, et al. Transforming growth factor-β1- induced expression of smooth muscle marker genes involves activation of PKN and p38 MAPK[ J ]. Journal of Biological Chemistry,2005, 280(35) :31172 -31181.
9Shimokawa H, Morishige K, Miyata K, et al. Long-term inhibition of Rho,kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo[ J]. Cardiovasc Res, 2001,51 ( 1 ) : 169 - 177.
10Weihua N, Shiro K, Minako I, et al. Monoeyte Chemoattraetant Protein-1 Is an Essential Inflammatory Mediator in Angiotensin Ⅱ-Induced Progression of Established Atherosclerosis in Hypercholesterolemic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology [ J ]. Arterioscler Thromb Vasc Biol,2004 ,24 :534 - 539.
